National Institute for Health and Clinical Excellence (NICE)
First gene therapy for rare genetic neurodegenerative disorder in children, recommended in NICE draft guidance
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Gene therapy atidarsagene autotemcel (also called Libmeldy and made by Orchard Therapeutics) will be available for some children with the rare, life-limiting inherited neurodegenerative condition metachromatic leukodystrophy (MLD).
Atidarsagene autotemcel is the first ever treatment for MLD and the draft guidance looks at its use in children with late infantile or early juvenile forms of MLD. It is thought there are around 5 children born each year in England with MLD.
Costing around £2.8 million at its list price, this one-off treatment is the most expensive drug NICE has ever evaluated. Following public consultation on NICE’s earlier draft guidance which did not recommend atidarsagene autotemcel, the company has increased the confidential discount to the price of the drug.
Atidarsagene autotemcel is given as a single-dose intravenous infusion. It is designed to correct the genetic cause of MLD by inserting functional copies of the faulty gene into the patient's own stem cells taken from their bone marrow or blood.
Clinical evidence suggests that atidarsagene autotemcel improves motor and cognitive function in the short term and could correct the enzyme deficiency caused by the disease.
The cost-effectiveness estimates show that atidarsagene autotemcel provides substantial extra health and quality-of-life benefits, although these vary for the different types of the disease.
Atidarsagene autotemcel is also recommended as an option for children with the early juvenile form of the condition who have early clinical symptoms but who can still walk independently and before the onset of cognitive decline.
Helen Knight, programme director in the Centre for Health Technology Evaluation at NICE, said:
“The independent committee recognised that MLD is a life-limiting, relentless, disabling and isolating condition, affecting all aspects of patients’ and caregivers’ lives. It also recognised that treatment options for MLD are limited to managing symptoms, and that there is a significant unmet need for disease-modifying therapies for MLD.
“The clinical evidence presented showed that for those children in whom atidarsagene autotemcel was effective, it had a substantial clinical benefit in terms of enabling children to maintain their motor and cognitive functions. We’re therefore pleased that the company has agreed an improved discount to the price of atidarsagene autotemcel which, in better reflecting the uncertainty in the evidence, has enabled the committee to recommend this potentially transformative treatment for children with this condition.”
MLD is caused by a lack of the enzyme Arylsulfatase-A. Without this enzyme, substances called sulphatides build up, eventually destroying the protective myelin sheath of the nervous system. As a result, the nerves in the brain and the peripheral nerves cease to function properly causing symptoms including peripheral neuropathy, muscle weakness, sight and hearing loss, difficulty walking, loss of speech, cognitive decline and seizures.
How quickly the disease progresses and how long children with it live varies based on age when symptoms appear. Children with the late infantile type of MLD - which starts before 30 months and is the most common and the most rapidly progressing type – deteriorate rapidly and usually die between the ages of 5 and 8. Children with early juvenile MLD, which usually starts between 30 months and 6 years, have a life expectancy between 10 and 20 years after onset.
Original article link: https://www.nice.org.uk/news/article/first-gene-therapy-for-rare-genetic-neurodegenerative-disorder-in-children-recommended-in-nice-draft-guidance
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Hundreds of people are set to receive the first immunotherapy drug for advanced cervical cancer through the Cancer Drugs Fund30/03/2023 11:05:00
Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE yesterday (Wednesday 29 March 2023) published the final draft guidance recommending its use in the Cancer Drugs Fund (CDF).
NICE identifies improvements for people with acute kidney injury in updated quality standard23/03/2023 15:30:00
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder in final draft guidance23/03/2023 13:15:00
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE in final draft guidance published today (23 March 2023).
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance21/03/2023 14:15:00
Innovative tests with the potential to help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly could soon be considered for use in the NHS.
NICE recommended weight-loss drug to be made available in specialist NHS services08/03/2023 14:20:00
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE01/03/2023 13:20:00
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance issued today (Wednesday 1 March 2023)
NICE recommends 3 treatments for COVID-19 in final draft guidance21/02/2023 13:05:00
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments, under final draft guidance published by NICE today.
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines16/02/2023 11:25:00
NICE has today (16 February 2023) issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in adults who are unlikely to have an adequate immune response to COVID-19 vaccination, or who can’t be vaccinated
New NICE quality standard identifies improvements in UTI diagnosis for women15/02/2023 15:10:00
Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms according to a new quality standard published by NICE today (15 February 2023).